Can I read Remission in Schizophrenia: One-Year Italian Prospective Study of Risperidone Long-Acting Injectable (RLAI) in Patients With Schizophrenia or Schizoaffective Disorder on EtoBox?
Remission in Schizophrenia: One-Year Italian Prospective Study of Risperidone Long-Acting Injectable (RLAI) in Patients With Schizophrenia or Schizoaffective Disorder by dr.cinta is a document available to read on EtoBox.
What is Remission in Schizophrenia: One-Year Italian Prospective Study of Risperidone Long-Acting Injectable (RLAI) in Patients With Schizophrenia or Schizoaffective Disorder about?
52-week, open-label prospective trial in 347 stable patients switching directly to RLAI from any previous antipsychotic treatment. 70% of patients met sustained remission at week 52. RLAI treatment was well tolerated: one-third of patients reported mild to moderate adverse events (AEs) Eleven patients (3.2%) discontinued treatment due to an AE.
- Author
- dr.cinta
- Language
- EN